Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microfracture plus autologous adipose-derived MSC injections for hip cartilage lesions
ACTRN12615000257561Phase 2Withdrawn
- Sponsor
- Magellan Stem Cells
- Start
- May 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in osteoarthritis (OA) and cartilage lesion of hip, sponsored by Magellan Stem Cells. Primary endpoints: Hip Injury and Osteoarthritis Outcome Score, Numerical Pain Rating Scale and 1 more. Planned start May 2015; status: withdrawn.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
osteoarthritis (OA)cartilage lesion of hip
Beyond the preview
Go deeper on ACTRN12615000257561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000257561.